Journal of Rheumatology最新文献_第2页

Obese Patients With Polymyalgia Rheumatica Experience More Pain And Disability At Disease Onset And Require Higher Doses Of Glucocorticoids. 肥胖的多发性风湿病患者在发病时会有更多的疼痛和残疾，并且需要更大剂量的糖皮质激素。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-11-01 DOI: 10.3899/jrheum.2024-0353

Marco A Cimmino, Cynthia S Crowson, Bhaskar Dasgupta, Michael Schirmer, Christian Dejaco, Carlo Salvarani, Eric L Matteson, Dario Camellino

{"title":"Obese Patients With Polymyalgia Rheumatica Experience More Pain And Disability At Disease Onset And Require Higher Doses Of Glucocorticoids.","authors":"Marco A Cimmino, Cynthia S Crowson, Bhaskar Dasgupta, Michael Schirmer, Christian Dejaco, Carlo Salvarani, Eric L Matteson, Dario Camellino","doi":"10.3899/jrheum.2024-0353","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0353","url":null,"abstract":"Objective: polymyalgia rheumatica (PMR) is an inflammatory disorder of the elderly characterized by girdle pain and stiffness. Obesity has an influence on disease activity and outcome in rheumatic diseases like osteoarthritis and rheumatoid arthritis, but its relationship to the severity and outcome of PMR is unknown.Methods: In a post-hoc analysis, 83 patients with recent-onset PMR were studied over six months with clinical examination, laboratory evaluation, and girdle ultrasound. MHAQ, Short Form 36 (SF36), and PMR-VAS, as well as prednisone (PDN) therapy were recorded. Patients were divided according to their body mass index (BMI).Results: at baseline, the 12 obese patients had significantly more shoulder pain (p=0.03), global pain (p=0.03), PMR VAS (p<0.01), and fatigue (p=0.03), higher MHAQ (p=0.01), and lower physical component summary on SF36 (p=0.048), SF36 social functioning index (p=0.05) and SF36 pain index (p<0.001). The mean initial PDN dose was similar among groups, but obese patients received a lower dose per kg weight (1.9±0.7 mg vs. 2.2±0.7 mg; p<0.01). At six months, obese patients were being treated with higher mean daily PDN doses (8.5±3.2 mg/day vs. 6.2±5.2 mg/day, p=0.02); 40% of them were receiving higher daily PDN dose than per-protocol, vs. 14% non-obese patients (p=0.048). Clinical features, laboratory and ultrasound results were similar.Conclusion: obesity affects both symptoms severity and PDN utilization in patients with PMR. The reason thereof may relate to different subjective pain perception rather than increased inflammation in obese patients. BMI should be considered when interpreting symptoms in PMR patients and deciding their PDN doses.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introducing "Rheumatology Around the World". 介绍 "世界各地的风湿病学"。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-11-01 DOI: 10.3899/jrheum.2024-0907

Earl D Silverman

引用次数: 0

Systemic Sclerosis Sine Scleroderma: A Time of Reappraisal. 无硬皮病的系统性硬化症：重新评估的时机。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-11-01 DOI: 10.3899/jrheum.2023-1113

Anastasios Makris, Alexandros Panagiotopoulos, Oliver Distler, Petros P Sfikakis

{"title":"Systemic Sclerosis Sine Scleroderma: A Time of Reappraisal.","authors":"Anastasios Makris, Alexandros Panagiotopoulos, Oliver Distler, Petros P Sfikakis","doi":"10.3899/jrheum.2023-1113","DOIUrl":"10.3899/jrheum.2023-1113","url":null,"abstract":"Objective: Systemic sclerosis sine scleroderma (ssSSc), formally described in 1962, is a subset of SSc that, unlike limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) forms, lacks skin fibrosis. According to the 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology criteria, SSc can be diagnosed in the absence of skin thickening, even if this is expected to develop later in disease course. Driven by a fatal case of ssSSc with cardiac involvement, we analyzed published data on ssSSc prevalence and severity.Methods: A systematic literature review and qualitative synthesis of SSc cohorts with data on ssSSc were performed.Results: Thirty-five studies involving a total of 25,455 patients with SSc, published between 1976 and 2023, were identified. Although different definitions were used, the mean prevalence of ssSSc was almost 10% (range 0-23%), with the largest study reporting a cross-sectional prevalence of 13%. In 5 studies with a follow-up period of up to 9 years, reclassification of ssSSc into lcSSc or dcSSc ranged 0-28%. Interstitial lung disease, pulmonary arterial hypertension, scleroderma renal crisis, and cardiac diastolic dysfunction were present in 46% (range 9.3-59.1%), 15% (range 5.9-24.6%), 5% (range 1.6-24.6%), and 26.5% (range 1.8-40.7), respectively, of patients with ssSSc. Survival across studies was comparable to lcSSc and better than dcSSc.Conclusion: Published data on ssSSc vary widely on prevalence, clinical expression, and prognosis, partly due to underdiagnosis and misclassification. Although classification criteria should not affect appropriate management of patients, updated ssSSc subclassification criteria that takes into account time from disease onset should be considered.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Remission Is the Mission in Gout. 缓解是痛风的使命

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-11-01 DOI: 10.3899/jrheum.2024-0921

Till Uhlig

引用次数: 0

Infected Tumoral Calcinosis Associated With Rheumatoid Arthritis. 类风湿性关节炎相关的感染性肿瘤钙化症

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-11-01 DOI: 10.3899/jrheum.2024-0761

Eri Sugawara, Keita Ninagawa, Kazuaki Katsumata

引用次数: 0

Mucosa-Associated Lymphoid Tissue Lymphoma as a Rare Mimicker of Relapsing Polychondritis. 粘膜相关淋巴组织淋巴瘤是复发性多软骨炎的罕见模仿者

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-11-01 DOI: 10.3899/jrheum.2024-0837

Norihisa Tada, Nao Oguro, Nobuyuki Yajima

引用次数: 0

Disparities in time to diagnosis of Radiographic Axial Spondyloarthritis. 轴性脊柱关节炎放射学诊断时间的差异。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-11-01 DOI: 10.3899/jrheum.2024-0574

Renato Ferrandiz-Espadin, Gabriela Rabasa, Sarah Gasman, Brooke McGinley, Rachael Stovall, S Reza Jafarzadeh, Jean W Liew, Maureen Dubreuil

{"title":"Disparities in time to diagnosis of Radiographic Axial Spondyloarthritis.","authors":"Renato Ferrandiz-Espadin, Gabriela Rabasa, Sarah Gasman, Brooke McGinley, Rachael Stovall, S Reza Jafarzadeh, Jean W Liew, Maureen Dubreuil","doi":"10.3899/jrheum.2024-0574","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0574","url":null,"abstract":"Objective: Radiographic axial spondyloarthritis (r-axSpA) has a 7-year average diagnostic delay. While the impact of sex or gender on time to diagnosis has been evaluated, the role of social determinants of health remains understudied. We assessed whether time from initial clinical documentation of r-axSpA symptoms to r-axSpA diagnosis (diagnostic delay) varies based on sex, race, ethnicity, or the presence of social needs.Methods: We studied patients with r-axSpA from a tertiary center from 2000 to 2022. The cohort was built with the Observational Health Data Sciences and Informatics (OHDSI) network. For the primary analysis, we assessed the time from back pain/spinal pain to r-axSpA diagnosis and secondarily, the time to r-axSpA from any other r-axSpA -related condition. To estimate differences in diagnostic delay, we employed a parametric survival model, accelerated failure time.Results: We included 404 patients (mean age 49, 37% female), with 25.5% identifying as Black, 31.1% as other or unknown race and 14.1% as Hispanic. Patients with a documented social need had a 21% increase in time from back pain to r-axSpA diagnosis (95% CI 0.93, 1.56). In patients with any r-axSpA related condition, time to diagnosis increased similarly by 21% (95% CI 0.92, 1.57). Considering an average time to diagnosis of 34 months, a social need increased time to diagnosis by 7 months.Conclusion: This study reveals a trend toward diagnostic delay in r-axSpA related to social need, sex, race, and ethnicity. Future studies should focus on referral strategies to enable prompt diagnosis and optimize care.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hydrocephalus-Related Dementia in Paget Disease of the Skull. 颅骨帕格特病中与脑积水相关的痴呆症

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-11-01 DOI: 10.3899/jrheum.2024-0818

João Daniel Ferreira Carvalho, José Carlos Romeu

引用次数: 0

Potential Efficacy of Janus Kinase Inhibitors in the Treatment of a Patient With Coexisting Peripheral and Axial Spondyloarthritis and Ulcerative Colitis. Janus 激酶抑制剂在治疗并存外周和轴性脊柱关节炎及溃疡性结肠炎患者中的潜在疗效。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-11-01 DOI: 10.3899/jrheum.2024-0055

Sho Ishigaki, Nobuhiko Kajio, Noritada Yoshikawa, Hiroaki Taguchi

引用次数: 0

Finding the Role of Anifrolumab in the New Paradigm of Systemic Lupus Erythematosus Treatment. 在系统性红斑狼疮治疗的新范例中寻找阿尼洛单抗的作用。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-11-01 DOI: 10.3899/jrheum.2024-0900

Romina Estefanía Nieto, Graciela S Alarcón, Laurent Arnaud, Guillermo Javier Pons-Estel

引用次数: 0